ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Phase 2

Completed

Conditions: NSCLC
Non Small Cell Lung Cancer

Interventions: Drug: Erlotinib
Drug: OSI-906
Drug: Placebo

First Posted Date: 2010-10-14

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 88

Registration Number: NCT01221077

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 26 locations

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Placebo
Drug: mirabegron
Drug: moxifloxacin

First Posted Date: 2010-09-13

Last Posted Date: 2013-07-03

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 352

Registration Number: NCT01199523

A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus

Phase 1

Completed

Conditions: Healthy
Pharmacokinetics of ASP015K and Tacrolimus

Interventions: Drug: Tacrolimus
Drug: ASP015K

First Posted Date: 2010-08-30

Last Posted Date: 2010-10-14

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 40

Registration Number: NCT01190670

A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941

Phase 1

Completed

Conditions: Liver Disease

Interventions: Drug: ASP1941

First Posted Date: 2010-08-23

Last Posted Date: 2010-10-07

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 16

Registration Number: NCT01187186

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Interventions: Drug: erlotinib
Drug: OSI-906
Drug: placebo

First Posted Date: 2010-08-23

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 205

Registration Number: NCT01186861

Locations: 🇺🇸
Site US10004, Greensboro, North Carolina, United States
🇵🇱
Site PL48005, Szczecin, Poland
🇷🇴
Site RO40005, Alba Iulia, Romania

and more 66 locations

A Study to Assess Drug Interaction of ASP015K and Midazolam

Phase 1

Completed

Conditions: Healthy
Pharmacokinetics of ASP015K and Midazolam

Interventions: Drug: ASP015K
Drug: Midazolam

First Posted Date: 2010-08-16

Last Posted Date: 2010-08-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 30

Registration Number: NCT01182077

A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients

Phase 4

Completed

Conditions: Primary Insomnia
Sleep Initiation and Maintenance Disorders

Interventions: Drug: Zolpidem IR
Drug: Zolpidem MR

First Posted Date: 2010-08-13

Last Posted Date: 2014-09-10

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 132

Registration Number: NCT01181232

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: ipragliflozin
Drug: Placebo
Drug: metformin

First Posted Date: 2010-06-02

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 168

Registration Number: NCT01135433

A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability

Phase 4

Completed

Conditions: Cognition

Interventions: Drug: Solifenacin
Drug: Placebo
Drug: Oxybutynin

First Posted Date: 2010-05-19

Last Posted Date: 2012-10-15

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 26

Registration Number: NCT01126424

A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B

Phase 1

Completed

Conditions: Healthy Volunteer
Pharmacokinetics of YM150

Interventions: Drug: YM150

First Posted Date: 2010-05-18

Last Posted Date: 2010-05-25

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 44

Registration Number: NCT01125657

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy